NeuroQuant PET has received FDA 510(k) clearance (K261916) for PET. The software is designed to aid physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for assessment of cognitive impairment and other neurological conditions.
NeuroQuant PET is described as delivering fully automated quantification, regional analysis, and structured reporting that integrates into routine clinical workflows.
The platform provides atlas-based quantification for amyloid PET tracers, generates standardized uptake value ratios and structured reports, and segments regions of interest while quantifying Centiloids for flutemetamol, florbetaben, and florbetapir. It is compatible with PET-CT, PET-MR, and PET-only workflows and produces PACS-ready outputs intended to bring quantitative metrics into existing imaging workflows.
Cortechs.ai is described as a developer of AI applications in radiology for assessing neurological disorders and other conditions.
